# A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity

Study · id `cardio:ct-nct07438444` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07438444](<https://clinicaltrials.gov/study/NCT07438444>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07438444

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 344 participants.

## Technical summary

Registry record NCT07438444. Allocation not applicable; no masking; primary purpose treatment. Start 2026-02-27 (actual); primary completion 2027-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 344 participants (planned count; ClinicalTrials.gov record NCT07438444, source copy `cardio:ctgov-nct07438444-2026-08-21`, retrieved 2026-10-26)
- Started: 2026-02-27 (actual) (ClinicalTrials.gov record NCT07438444, source copy `cardio:ctgov-nct07438444-2026-08-21`, retrieved 2026-10-26)
- Primary completion: 2027-07 (anticipated) (ClinicalTrials.gov record NCT07438444, source copy `cardio:ctgov-nct07438444-2026-08-21`, retrieved 2026-10-26)
- Completion: 2027-07 (anticipated) (ClinicalTrials.gov record NCT07438444, source copy `cardio:ctgov-nct07438444-2026-08-21`, retrieved 2026-10-26)
- Countries: India (ClinicalTrials.gov record NCT07438444, source copy `cardio:ctgov-nct07438444-2026-08-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07438444-2026-08-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity
- Condition: Diabetes Mellitus, Type 2
- Condition: Obesity
- Condition: Overweight
- Intervention (Drug): Tirzepatide
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Tirzepatide (`cardio:tirzepatide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 246a279817de31c80e1855b569ac1a3a0656a3898f0083789d8b794867f7e44e
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
